Mesoblast ADRs Rise 22%, Company Joining Nasdaq Biotechnology Index

Dow Jones

Dec 19, 2024

By Stephen Nakrosis

The American depositary receipts of Mesoblast were trading higher after hours Wednesday following news the Food and Drug Administration approved its Ryoncil as a treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.

Also on Wednesday, the company said it will be added to the Nasdaq Biotechnology Index, effective Dec. 23.

After the bell, the company's ADRs were trading 22% higher, at $14.98. They ended the day's regular session with a 2% loss, closing at $12.25.

Mesoblast said it develops allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

December 18, 2024 19:11 ET (00:11 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2492166865"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492166865\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2492166865?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-19 07:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492166865","market":"fut","top_or_hot":-1,"title":"Mesoblast ADRs Rise 22%, Company Joining Nasdaq Biotechnology Index","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  The American depositary receipts of Mesoblast were trading higher after hours Wednesday following news the Food and Drug Administration approved its Ryoncil as a treatment of steroid-refractory acute graft-versus-host disease in pediatric patients. \n</p>\n<p>\n  Also on Wednesday, the company said it will be added to the Nasdaq Biotechnology Index, effective Dec. 23. \n</p>\n<p>\n  After the bell, the company's ADRs were trading 22% higher, at $14.98. They ended the day's regular session with a 2% loss, closing at $12.25. \n</p>\n<p>\n  Mesoblast said it develops allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 18, 2024 19:11 ET (00:11 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesoblast ADRs Rise 22%, Company Joining Nasdaq Biotechnology Index</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesoblast ADRs Rise 22%, Company Joining Nasdaq Biotechnology Index\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-19 07:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  The American depositary receipts of Mesoblast were trading higher after hours Wednesday following news the Food and Drug Administration approved its Ryoncil as a treatment of steroid-refractory acute graft-versus-host disease in pediatric patients. \n</p>\n<p>\n  Also on Wednesday, the company said it will be added to the Nasdaq Biotechnology Index, effective Dec. 23. \n</p>\n<p>\n  After the bell, the company's ADRs were trading 22% higher, at $14.98. They ended the day's regular session with a 2% loss, closing at $12.25. \n</p>\n<p>\n  Mesoblast said it develops allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 18, 2024 19:11 ET (00:11 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和数据","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492166865","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492166865","pubTimestamp":1734564000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"The American depositary receipts of Mesoblast were trading higher after hours Wednesday following news the company will be added to the Nasdaq Biotechnology Index, effective Dec. 23.After the bell, the company's ADRs were trading 22% higher, at $14.98. They ended the day's regular session with a 2% loss, closing at $12.25.Mesoblast said it develops allogeneic  cellular medicines for the treatment of severe and life-threatening inflammatory conditions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","QID":"两倍做空纳斯达克指数ETF-ProShares","USAW.SI":"AMZN 3xLongSG261006","PSQ":"做空纳斯达克100指数ETF-ProShares",".IXIC":"NASDAQ Composite","TQQQ":"纳指三倍做多ETF","MESO":"Mesoblast Limited","BK4585":"ETF&股票定投概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK7508":"医药生物股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股","BK7501":"新冠治疗股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4139":"生物科技","NDAQ":"纳斯达克OMX交易所","NVIW.SI":"NVDA 3xLongSG261006","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","USJW.SI":"ALPHAB 3xLongSG261006","TSYW.SI":"TESLA 3xLongSG261006","BK7067":"生物科技","QLD":"2倍做多纳斯达克100指数ETF-ProShares","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","MSB.AU":"MESOBLAST LTD","SQQQ":"纳指三倍做空ETF"},"translate_title":"Mesoblast ADR上涨22%，公司加入纳斯达克生物技术指数","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TQQQ":0.6,"PSQ":0.6,"SQQQ":0.6,"NDAQ":1,"QID":0.6,"MNQmain":0.6,"TSYW.SI":0.6,"MSB.AU":0.9,"NQmain":1,"USJW.SI":0.6,"NVIW.SI":0.6,"USAW.SI":0.6,"QLD":0.6,"MESO":1,".IXIC":1},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  The American depositary receipts of Mesoblast were trading higher after hours Wednesday following news the Food and Drug Administration approved its Ryoncil as a treatment of steroid-refractory acute graft-versus-host disease in pediatric patients. \n\n\n  Also on Wednesday, the company said it will be added to the Nasdaq Biotechnology Index, effective Dec. 23. \n\n\n  After the bell, the company's ADRs were trading 22% higher, at $14.98. They ended the day's regular session with a 2% loss, closing at $12.25. \n\n\n  Mesoblast said it develops allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 18, 2024 19:11 ET (00:11 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}